Vincristine combination with Ca+2 channel blocker increase antitumor effects

Mol Biol Rep. 2019 Apr;46(2):2523-2528. doi: 10.1007/s11033-019-04706-w. Epub 2019 Mar 22.

Abstract

In this study, it was aimed to determine the effects of Amlodipine, a calcium channel blocker and vincristine (VCR) an antineoplastic, on human neuroblastomas using different doses. The cytotoxicity assays of the study were performed using the MTT method depending on time and concentration. After obtaining the mixture (up to 85% for SH-SY5Y) and sufficient branches (cortex neurons), the cells were treated with amlodipine (10 µM) and vincristine (0.5, 1 and 2 µg) at different concentrations for 24 h. MTT assay was performed by the commercially available kit (Sigma Aldrich, USA). Cells were harvested, washed and stained with PI and Annexin V, respectively, according to the manufacturer's protocol (Biovision, USA). Than analyzes were carried out. The results were quite impressive. When amlodipine (10 µM) was administered alone there was little change compared to the control. However, all doses of amlodipine (10 µM) and vincristine (0.5, 1 and 2 µg) were greater than the deaths in the doses alone (0.5, 1 and 2 µg) of vincristine alone. (P < 0.05). As a result, the combination of vincristine and amlodipine is more effective than vincristine alone in reducing the viability of cancer cells.

Keywords: Amlodipine; Calcium channel blockers; Neuroblastoma; Vincristine.

MeSH terms

  • Amlodipine / metabolism
  • Amlodipine / pharmacology
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Calcium Channel Blockers / pharmacology
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Humans
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / metabolism
  • Vincristine / metabolism*
  • Vincristine / pharmacology*

Substances

  • Antineoplastic Agents
  • Calcium Channel Blockers
  • Amlodipine
  • Vincristine